Randomized Phase 3 Open Label Study - Enzastaurin vs. Lomustine in Glioblastoma

Inclusion Criteria:

1. Patient presents with histologically confirmed diagnosis of brain cancer
(specifically glioblastoma multiforme).

2. Your cancer has returned following therapy.

3. Patient may have undergone prior surgery to remove cancer.

4. Patient must be able to care for self.

Exclusion Criteria:

1. Have a second type of cancer (except adequately treated basal cell carcinoma of the
skin). Patient who has had another cancer in the past, must be free of cancer for
more than 2 years.

2. Have received treatment within the last 30 days with a drug that has not received
regulatory approval for any indication at the time of entry.

3. Patients receiving medication for seizures must discontinue 14 days prior to
enrolling.

4. Cannot be on blood thinning medication at study enrollment.

5. Cannot be on other medicines to prevent cancer at study enrollment.

6. Patients are not allowed to enter the study if they have previously taken
Enzastaurin, Lomustine and/or Bevacizumab.